VYNE Therapeutics Inc. (VYNE)
VYNE Therapeutics Statistics
Share Statistics
VYNE Therapeutics has 14.75M shares outstanding. The number of shares has increased by 4.63% in one year.
| Shares Outstanding | 14.75M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.01% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 12.70M |
| Failed to Deliver (FTD) Shares | 53.44K |
| FTD / Avg. Volume | 47.43% |
Short Selling Information
The latest short interest is 62.38K, so 0.42% of the outstanding shares have been sold short.
| Short Interest | 62.38K |
| Short % of Shares Out | 0.42% |
| Short % of Float | 0.49% |
| Short Ratio (days to cover) | 0.83 |
Valuation Ratios
The PE ratio is -0.84 and the forward PE ratio is -3.49.
| PE Ratio | -0.84 |
| Forward PE | -3.49 |
| PS Ratio | 56.45 |
| Forward PS | 135.2 |
| PB Ratio | 0.27 |
| P/FCF Ratio | -0.94 |
| PEG Ratio | n/a |
Enterprise Valuation
VYNE Therapeutics Inc. has an Enterprise Value (EV) of -6.52M.
| EV / Earnings | 0.23 |
| EV / Sales | -15.39 |
| EV / EBITDA | 0.22 |
| EV / EBIT | 0.22 |
| EV / FCF | 0.26 |
Financial Position
The company has a current ratio of 12.73, with a Debt / Equity ratio of 0.
| Current Ratio | 12.73 |
| Quick Ratio | 12.73 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.24 |
| Cash Flow / Debt | -118.42 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.32% and return on capital (ROIC) is -32.89%.
| Return on Equity (ROE) | -0.32% |
| Return on Assets (ROA) | -0.29% |
| Return on Capital (ROIC) | -32.89% |
| Revenue Per Employee | 42.40K |
| Profits Per Employee | -2.85M |
| Employee Count | 10 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 52.78% in the last 52 weeks. The beta is 1.35, so VYNE Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.35 |
| 52-Week Price Change | 52.78% |
| 50-Day Moving Average | 2.9 |
| 200-Day Moving Average | 2.38 |
| Relative Strength Index (RSI) | 45.21 |
| Average Volume (20 Days) | 112.68K |
Income Statement
In the last 12 months, VYNE Therapeutics had revenue of 424.00K and earned -28.45M in profits. Earnings per share was -2.77.
| Revenue | 424.00K |
| Gross Profit | 424.00K |
| Operating Income | -29.26M |
| Net Income | -28.45M |
| EBITDA | -29.26M |
| EBIT | -29.26M |
| Earnings Per Share (EPS) | -2.77 |
Balance Sheet
The company has 30.62M in cash and 214.00K in debt, giving a net cash position of 30.41M.
| Cash & Cash Equivalents | 30.62M |
| Total Debt | 214.00K |
| Net Cash | 30.41M |
| Retained Earnings | -691.34M |
| Total Assets | 76.20M |
| Working Capital | 60.87M |
Cash Flow
In the last 12 months, operating cash flow was -25.34M and capital expenditures 0, giving a free cash flow of -25.34M.
| Operating Cash Flow | -25.34M |
| Capital Expenditures | 0 |
| Free Cash Flow | -25.34M |
| FCF Per Share | -2.47 |
Margins
Gross margin is 100%, with operating and profit margins of -6.90K% and -6.71K%.
| Gross Margin | 100% |
| Operating Margin | -6.90K% |
| Pretax Margin | -6.57K% |
| Profit Margin | -6.71K% |
| EBITDA Margin | -6.90K% |
| EBIT Margin | -6.90K% |
| FCF Margin | -5.98K% |
Dividends & Yields
VYNE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -100.73% |
| FCF Yield | -62.47% |
Analyst Forecast
The average price target for VYNE is $6.88, which is 150.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.88 |
| Price Target Difference | 150.2% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Feb 13, 2023. It was a backward split with a ratio of 1:18.
| Last Split Date | Feb 13, 2023 |
| Split Type | backward |
| Split Ratio | 1:18 |
Scores
| Altman Z-Score | -11.91 |
| Piotroski F-Score | 2 |